Existing users please login

Forgot Password

    Home / Markets / Industries / Health Care

    Tuesday, November 17, 2009

    InterMune Shares Fall on Drug Study

    | Respond to Editor | Print

     
    By Darryl R. Isherwood
    FOXBusiness
       

      InterMune Inc. (ITMN), currently conducting a study of its hepatitis C drug, said it would discontinue studying a high level dose amid fears of liver damage.

      The biotech firm said an independent monitoring committee recommended the company discontinue testing its 900 milligram dose in a mid-stage study after three patients had elevated levels of a liver enzyme.

      Analysts are looking at study data to see if the safety issue is present in two lower doses.

      The announcement sent the shares down 17% Tuesday to $11.81.

      Fox Business Video


      Last 5 Stocks

      • Ticker
      • Company
      • Price
      • Change
       

      Personal Finance - Investing - Financial News - Business News - Stock Market Quotes & News - Small Business

      Advertise with us | Jobs at FOX Business Network | Internships at FBN

      Terms of use. Privacy Statement. For FOXBusiness.com technical issues write to foxbusinessonline@foxbusiness.com; for all other feedback, write to feedback@foxbusiness.com.

      Quotes delayed at least 15 minutes. Market Data provided by Interactive Data (Terms & Conditions). Powered and implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions.

      This material may not be published, broadcast, rewritten, or redistributed. ©2010 FOX News Network, LLC. All rights reserved.